Technology area: Biotechnology & Pharmaceuticals
45 pending office actions • 37 art units • 45 examiners • 2 of 45 (4%) have an AI response strategy ready • 15 patents granted in the last 365 days
Otsuka Pharmaceutical Co., Ltd. has 47 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 47 distinct examiners across 36 distinct art units, indicating that each pending matter has a separate examiner assignment while some art-unit settings recur.
KUCHARCZK, JED A is the busiest examiner, with 1 pending matter. The absence of repeated examiner assignments makes centralized prosecution procedures, consistent technical positions, and application-level review the practical management priorities.
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 3 (7%) |
| §103 only | 10 (22%) |
| §102 only | 3 (7%) |
| §112 only | 3 (7%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 6 (13%) |
| Multi-statute (no §101) | 18 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMALLEY, JAMES N | 1 | 70.7% | -9.8% |
| HAGOPIAN, CASEY SHEA | 1 | 54.3% | +33.4% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
| NGO, MEAGAN N | 1 | 58.3% | +33.7% |
| O'HERN, BRENT T | 1 | 78.5% | +19.4% |
| CHEN, VIVIAN | 1 | 56.6% | +28.5% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
| PHAN, DOAN THI-THUC | 1 | 42.8% | +47.6% |
| REGLAS, GEORGIANA C | 1 | 39.2% | +33.4% |
| KOO, BENJAMIN K | 1 | 57.3% | +49.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16863187 | EQUOL-CONTAINING EXTRACT, METHOD FOR PRODUCTION THEREOF, METHOD FOR EXTRACTION OF EQUOL, AND EQUOL-CONTAINING FOOD | LANDAU, SHARMILA GOLLAMUDI | 142d overdue |
| 18023211 | KAEMPFEROL AGLYCONE-CONTAINING EXTRACT | DAHLIN, HEATHER RAQUEL | 37d overdue |
| 18683025 | INFORMATION PROVISION METHOD FOR PREDICTING HEALTH CONDITION OF CONSUMER AND SUPPORTING HEALTH MAINTENANCE AND IMPROVEMENT | HEIN, DEVIN C | 35d overdue |
| 19098406 | CONTENT PROCESSING METHOD AND COMPUTER-READABLE MEDIUM | JACOB, AJITH | 15d overdue |
| 18042167 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | KAPUSHOC, STEPHEN THOMAS | 19d |
| 17397911 | AMELIORATING AGENT FOR FEMALE-SPECIFIC PHYSICAL AND/OR MENTAL UNPLEASANT SYMPTOM | BARSKY, JARED | 22d |
| 19045529 | ENDOSCOPE VISUAL FIELD-SECURING VISCOELASTIC COMPOSITION | HAGOPIAN, CASEY SHEA | — |
| 18839933 | SYRINGE FOR CRYOPRESERVATION | NGO, MEAGAN N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17438025 | STORAGE LIQUID FOR MAMMALIAN CELLS | REGLAS, GEORGIANA C | 97d overdue |
| 18007323 | NUTRITION FORMULATION | DABKOWSKI, ERINNE R | 37d overdue |
| 19045529 | ENDOSCOPE VISUAL FIELD-SECURING VISCOELASTIC COMPOSITION | HAGOPIAN, CASEY SHEA | — |
| 18842107 | OIL-IN-WATER EMULSION COMPOSITION | ARNOLD, ERNST V | — |
| 18839933 | SYRINGE FOR CRYOPRESERVATION | NGO, MEAGAN N | — |
| 18576582 | ENTERAL NUTRIENT PREPARATION | O'HERN, BRENT T | — |
| 18284014 | MULTILAYER FILM AND LIQUID AGENT CONTAINER | CHEN, VIVIAN | — |
| 17926082 | ENCAPSULATED PANCREATIC ISLET | PHAN, DOAN THI-THUC | — |
| Art Unit | Apps |
|---|---|
| 1613 | 4 |
| 1623 | 2 |
| 1615 | 2 |
| 1621 | 2 |
| 1628 | 2 |
| 1647 | 2 |
| 3733 | 1 |
| 1617 | 1 |
| 3781 | 1 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19144109 | MEDICAL CAP, MEDICAL CONTAINER, AND METHOD FOR MANUFACTURING MEDICAL CAP | SMALLEY, JAMES N | 3733 | §102 | Non-Final OA | — | Pending | Jun 27, 2025 |
| 19045529 | ENDOSCOPE VISUAL FIELD-SECURING VISCOELASTIC COMPOSITION | HAGOPIAN, CASEY SHEA | 1617 | §102§103§112 | Non-Final OA | — | Pending | Feb 04, 2025 |
| 18842107 | OIL-IN-WATER EMULSION COMPOSITION | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18839933 | SYRINGE FOR CRYOPRESERVATION | NGO, MEAGAN N | 3781 | §102§103 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18576582 | ENTERAL NUTRIENT PREPARATION | O'HERN, BRENT T | 1793 | §102 | Final Rejection | — | Pending | Jan 04, 2024 |
| 18284014 | MULTILAYER FILM AND LIQUID AGENT CONTAINER | CHEN, VIVIAN | 1787 | §103 | Final Rejection | — | Pending | Sep 25, 2023 |
| 18007323 | NUTRITION FORMULATION | DABKOWSKI, ERINNE R | 1654 | §102§103§112DP | Final Rejection | 37d overdue | Pending | Jan 30, 2023 |
| 17926082 | ENCAPSULATED PANCREATIC ISLET | PHAN, DOAN THI-THUC | 1613 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2022 |
| 17438025 | STORAGE LIQUID FOR MAMMALIAN CELLS | REGLAS, GEORGIANA C | 1651 | §103 | Non-Final OA | 97d overdue | Pending | Sep 10, 2021 |
| 17418714 | MEDICINE ADMINISTERING DEVICE AND MEDICINE ADMINISTERING SYSTEM | KOO, BENJAMIN K | 3783 | §102§103 | Final Rejection | — | Pending | Jun 25, 2021 |
| 19220457 | METHODS OF DISPERSING ARIPIPRAZOLE INJECTABLE PREPARATIONS | KUCHARCZK, JED A | 1623 | §103DP | Final Rejection | 46d overdue | AI Ready | May 28, 2025 |
| 18867205 | MICROORGANISM BELONGING TO GENUS AKKERMANSIA | DAVIS, RUTH A | 1699 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18917591 | FROZEN DESSERT COMPOSITION | MERRIAM, ANDREW E | 1791 | §103 | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18907757 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | BAEK, BONG-SOOK | 1611 | §102§103DP | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18850660 | WOUND TREATMENT COMPOSITION | SHIM, DAVID M. | 1626 | §103§112 | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18815060 | ORAL PHARMACEUTICAL COMPOSITION | TRAN, SUSAN T | 1615 | §102§103 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18814803 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | WILSON, JERICA KATLYNN | 1621 | §103§112Other | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18840444 | COMBINATION FORMULATION OF CEDAZURIDINE | PACKARD, BENJAMIN J | 1612 | §102§103 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18785196 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | CHONG, YONG SOO | 1623 | §103 | Final Rejection | — | Pending | Jul 26, 2024 |
| 18744247 | KAEMPFEROL ANALOG-CONTAINING COMPOSITION | MCINTOSH III, TRAVISS C | 1693 | DP | Final Rejection | — | Pending | Jun 14, 2024 |
| 18679934 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | MOU, LIYUAN | 1628 | §112DP | Non-Final OA | — | Pending | May 31, 2024 |
| 18662049 | INJECTABLE PREPARATION | AL-AWADI, DANAH J | 1615 | §112DP | Non-Final OA | — | Pending | May 13, 2024 |
| 18702752 | COMPOSITIONS COMPRISING AN ERK INHIBITOR | SONG, JIANFENG | 1613 | §103§112Other | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18693727 | METHODS OF TREATING MYELODYSPLASTIC SYNDROMES WITH DECITABINE AND CEDAZURIDINE | LEWIS, PATRICK T | 1691 | §102§103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18689319 | ACRIDINE COMPOUND | MAHLUM, JONATHAN DAVIS | 1625 | §102 | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18685103 | COMBINATION DRUG | ALDARONDO, DASIA ALI | 1647 | §103 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18683025 | INFORMATION PROVISION METHOD FOR PREDICTING HEALTH CONDITION OF CONSUMER AND SUPPORTING HEALTH MAINTENANCE AND IMPROVEMENT | HEIN, DEVIN C | 3686 | §101§102§103§112 | Final Rejection | 35d overdue | Pending | Feb 12, 2024 |
| 18568772 | PROCESS FOR PREPARING AN ERK INHIBITOR | BORALSKY, LUKE ALAN | 1624 | §103§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18466911 | PD-1 AGONIST ANTIBODIES | DONOGHUE, BRITTNEY ERIN | 1675 | §112 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18461170 | CLIPTAC COMPOSITION | PUTTLITZ, KARL J | 1646 | §102§112Other | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18023211 | KAEMPFEROL AGLYCONE-CONTAINING EXTRACT | DAHLIN, HEATHER RAQUEL | 1629 | §102§112 | Final Rejection | 37d overdue | Pending | Feb 24, 2023 |
| 18042167 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112 | Final Rejection | 19d | Pending | Feb 17, 2023 |
| 18006969 | BLADDER ORGANOID AND METHOD FOR PRODUCING SAME | WILSON, MICHAEL C | 1638 | §112 | Final Rejection | 15d overdue | Pending | Jan 26, 2023 |
| 17923182 | METHODS FOR SYNTHESIZING ANHYDROUS LACTIC ACID | BAZARGANI, ARYA AHMADI | 1600 | §112 | Non-Final OA | — | Pending | Nov 03, 2022 |
| 17923188 | IAP ANTAGONIST COMPOUNDS AND INTERMEDIATES AND METHODS FOR SYNTHESIZING THE SAME | O DELL, DAVID K | 1621 | §103 | Final Rejection | — | Pending | Nov 03, 2022 |
| 17755832 | ORALLY DISINTEGRATING TABLET | PALENIK, JEFFREY T | 1614 | §103 | Non-Final OA | — | AI Ready | Jun 10, 2022 |
| 17782469 | STANDARD SUBSTANCE FOR PSA QUANTIFICATION, PREPARATION METHOD THEREFOR, STANDARD SOLUTION FOR PSA QUANTIFICATION, AND PSA QUANTIFICATION METHOD | DEBERRY, REGINA M | 1647 | §102§103§112 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17606276 | HIGH VISCOSITY O/W EMULSION COMPOSITION CONTAINING ADENOSINE PHOSPHATE | BERRIOS, JENNIFER A | 1613 | §103 | Non-Final OA | — | Pending | Oct 25, 2021 |
| 17433904 | COMPOSITION CONTAINING PLANT-DERIVED EXTRACT AND/OR PLANT-DERIVED PROCESSED PRODUCT | MOEHLMAN, ANDREW TERRY | 1655 | §103DP | Non-Final OA | 98d overdue | Pending | Aug 25, 2021 |
| 17397911 | AMELIORATING AGENT FOR FEMALE-SPECIFIC PHYSICAL AND/OR MENTAL UNPLEASANT SYMPTOM | BARSKY, JARED | 1628 | §103§112 | Final Rejection | 22d | Pending | Aug 09, 2021 |
| 16863187 | EQUOL-CONTAINING EXTRACT, METHOD FOR PRODUCTION THEREOF, METHOD FOR EXTRACTION OF EQUOL, AND EQUOL-CONTAINING FOOD | LANDAU, SHARMILA GOLLAMUDI | 1653 | §103§112 | Final Rejection | 142d overdue | Pending | Apr 30, 2020 |
| 19098406 | CONTENT PROCESSING METHOD AND COMPUTER-READABLE MEDIUM | JACOB, AJITH | 2161 | §101 | Final Rejection | 15d overdue | Pending | Apr 02, 2025 |
| 18627228 | CONTENT PROCESSING METHOD AND COMPUTER-READABLE MEDIUM | WEAVER, ADAM MICHAEL | 2658 | §101§103 | Final Rejection | — | Pending | Apr 04, 2024 |
| 18574520 | RUBBER COMPOSITION AND TIRE | FISCHER, JUSTIN R | 1749 | §103 | Non-Final OA | 12d | Pending | Dec 27, 2023 |
| 18563617 | EPOXY RESIN MODIFIER, EPOXY RESIN COMPOSITION CONTAINING SAME, ADHESIVE COMPOSED OF EPOXY RESIN COMPOSITION, AND RESIN CURED PRODUCT OBTAINED BY CURING EPOXY RESIN COMPOSITION | ZHANG, RUIYUN | 1782 | §102§103 | Non-Final OA | — | Pending | Nov 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOtsuka Pharmaceutical Co., Ltd. has 45 pending office actions as of October 2026, spread across 37 art units and 45 examiners.
James N Smalley has the most, with 1 of Otsuka Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
